Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

Tanaka, Masami; Oikawa, Kosuke; Takanashi, Masakatsu; Kudo, Motoshige; Ohyashiki, Junko H.; Ohyashiki, Kazuma; Kuroda, Masahiko

doi:10.1371/journal.pone.0005532

Cited by 274 publications

(245 citation statements)

References 32 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…[20] Comparison of the ratio of miRNA-92a signal intensity (0.239 ± 0.286) to miR-NA-638 signal intensity by TaqMan qRT-PCR among the plasmas of AML and control samples (0.969 ± 0.490) determined statistical significance difference (p = 0.000) this confirmed downregulation in plasma of miRNA-92a in AML patients This result was in agreement with the study carried out by Tanaka et al [17] on the plasma samples from normal (n = 16) and leukemia (AML, n = 54; ALL, n = 7) by TaqMan qRT-PCR. They reported that miRNA-638 is stably present in human plasmas, and miRNA-92a dramatically decreased in the plasmas of acute leukemia patients.…”

Section: Discussionsupporting

confidence: 89%

“…As miRNA-92a is expressed in the majority of cells at all times, its expression profiles will form a reliable part of diagnosis and detection of disease [17]. The search for noninvasive tools for diagnosis and management of cancer is extremely important for reducing the world wide health burden of cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies, however, have revealed that microRNAs exist and escape digestion in plasma [17]. So that trial to document the use of microRNAs as noninvasive method that may help in the diagnosis, prognosis and the plan of therapy in AML is justified.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia

Elhalawani¹,

Hamed²,

Eldafrawi³

et al. 2014

AJMB

View full text Add to dashboard Cite

Background: MicroRNAs (miRNAs) are short noncoding RNAs of ~21 to 23 nucleotides in length that post-transcriptionally regulate mRNA expression. Highthroughput methodologies have shown deregulated miRNA expression in an increasing number of human cancers. MiRNA expression patterns have been found to distinguish tumors of different developmental origin, even better than traditional mRNA expression profiling. Aim: To assess the plasma level of micro-RNA-92a in adult acute myeloid leukemia and to correlate it with prognostic factors and therapeutic response. Patients and Methods: This study was carried out on fifty AML patients as well as fifty healthy subjects as control. Conventional cytogenetics was performed on patients group only while measurement of the plasma level of miRNA-92a using TaqMan quantitative RT-PCR with miRNA-638 as endogenous reference for standardization and FLT3/ITD mutation was performed on patients and controls. Results: The differences in the ratio or relative quantitation (RQ) of plasma miRNa-92a to miRNA-638 in patients group to the control group have confirmed statistical significance. Also there was significant negative correlation between RQ of miRNA-92a and white blood count in patient group. Patients who achieved a response after induction chemotherapy had a mean RQ of miRNA-92a higher than non-responder with statistical significance. With regard to cytogenetics, favorable risk cytogenetics had meant RQ of miRNA-92a that was comparable to intermediate risk cytogenetics. While poor risk cytogenetics had a mean RQ which is significantly lower than both favorable and intermediate risk cytogenetics. Summary/Conclusions: Our data suggest the potential importance of the microRNA-92a as noninvasive cancer biomarkers helping in diagnosis, clinical prediction and therapeutic response.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia

Elhalawani¹,

Hamed²,

Eldafrawi³

et al. 2014

AJMB

View full text Add to dashboard Cite

show abstract

“…Other studies, however, have shown that there is a strong correlation between elevated microRNA levels, such as miR-92a, in plasma and leukemic cells, suggesting an important role in cellular communication. [44][45][46] In summary, we performed global microRNA expression profiling on plasma samples from 72 patients with de novo myelodysplastic syndromes and 12 healthy individuals (controls). We identified a number of microRNAs that are potential noninvasive biomarkers for diagnosis and prognostication.…”

Section: Discussionmentioning

confidence: 99%

Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes

Zuo

Maiti

Hu³

et al. 2015

Modern Pathology

View full text Add to dashboard Cite

Myelodysplastic syndromes are a heterogeneous group of clonal bone marrow hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. Chromosomal abnormalities and gene mutations have been shown to have essential roles in pathogenesis and correlate with prognosis. Molecular markers, however, are not integrated into currently used prognostic systems. The goal of this study is to identify plasma microRNAs useful for classification and risk stratification of myelodysplastic syndromes. We applied a novel, high-throughput digital quantification technology (NanoString) to profile microRNA expression in plasma samples of 72 patients with myelodysplastic syndromes and 12 healthy individuals. We correlated these results with overall survival. In patients with myelodysplastic syndromes associated with a diploid karyotype, we identified and validated a 7-microRNA signature as an independent predictor of survival with a predictive power of 75% accuracy (P ¼ 0.008), better than those of the International Prognostic Scoring Systems and the MD Anderson Prognostic Lower Risk Prognostic Model. We also identified differentially expressed plasma microRNAs in patients with myelodysplastic syndromes versus healthy individuals and between patients with myelodysplastic syndromes associated with different cytogenetic features. These results validate the utility of circulating-microRNA levels as noninvasive biomarkers that can inform the management of patients with myelodysplastic syndromes. Our findings also shed light on interactions of gene regulation pathways that are likely involved in the pathogenesis of myelodysplastic syndromes.

show abstract

“…Every cancer investigated has a distinct miRNA signature and deregulated levels of miRNAs have been detected in body fl uids of patients, including those with lymphoma, [11] leukemia, [12] colon, [13] breast, [14] prostate, [15] ovarian, [16] pancreatic, [17] gastric, [18] and lung cancer. [19] In the context of brain tumors, recent studies have demonstrated a signifi cant presence of certain miRNAs in CSF samples from patients with central nervous system lymphoma, glioma, and metastatic brain cancers.…”

Section: Introductionmentioning

confidence: 99%

Detection and quantification of extracellular microRNAs in medulloblastoma

Shalaby¹,

Fiaschetti²,

Baulande³

et al. 2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Aim: Medu lloblastoma (MB) is the most common malignant brain tumor in children. The crucial role of extracellular-microRNAs (ex-miRNAs) in cancer has been widely recognized; however, their role in MB remains unknown. This study aimed to investigate MB-driven ex-miRNAs. Methods: Microarray analysis was used to disclose the identity and quantity of key miRNAs excreted in culture-medium (CM) of 3 human MB cell lines and cere brospinal fl uid (CSF) of brain tumors (including MB) and leukemia patients. MiRNA expression was validated by quantitative reverse transcription polymerase chain reaction. Results: We have demonstrated that the 3 MB cell lines tested commonly expressed 1,083 miRNAs in their spent CM. Among them, 57 miRNAs were specifi c to the CM of metastasis-related cell lines which represents the aggressive group 3 and group 4 MB subtypes. A signifi cant number (1,254) of ex-miRNAs were identifi ed in the CSF of a MB patient. Eighty-six of these miRNAs were found to be differentially expressed in this patient's CSF compared with controls. Interestingly, 3 metastasis-associated miRNAs over-represented in CM of metastasis-related MB cell lines were found to be signifi cantly enriched in the CSF of the MB patient. Conclusion: Although more samples are required to fully verify these results, our work provides the fi rst evidence for the presence of a signifi cant amount of miRNAs excreted extracellularly by MB cells and raises the possibility that, in the near future, miRNAs could be probed in CSF of MB patients and serve as novel biological markers.

show abstract

Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients

Cited by 274 publications

References 32 publications

Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia

Diagnostic and prognostic value of plasma level of microRNA-92a in acute myeloid leukemia

Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes

Detection and quantification of extracellular microRNAs in medulloblastoma

Contact Info

Product

Resources

About